AI-enhanced algorithm improves diagnosis of REM sleep behavior disorder

A Mount Sinai-led team of researchers has enhanced an artificial intelligence (AI)-powered algorithm to analyze video recordings of clinical sleep tests, ultimately improving accurate diagnosis of a common sleep disorder affecting more than 80 million people worldwide.

Approval of Bevacizumab Biosimilar for Ophthalmic Use Could Upend Low-Cost Anti-VEGF

CHICAGO — Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a wide variety of off-label indications and add

October 25, 2024

Vertex’s next challenge for pain pill? Cracking a market dominated by cheap opioids

How do you compete against a drug that costs mere cents? On Tuesday, Vertex succeeded where many drugmakers have tried and failed — it produced

January 31, 2024

ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours

Sacituzumab tirumotecan is a trophoblast cell-surface antigen 2 (TROP2) targeting antibody linked to linked to a belotecan-derivative topoisomerase I inhibitor payload. Image Credit: testing /

May 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.